PIK3CA, the gene which encodes for p110α PI3K, is mutated in a variety of tumor types [25–27] and BYL719 is a specific class-IA PI3K inhibitor, which acts by binding the ATP-binding domain of the p110α subunit [28]. This evidence concerns the gene PIK3CA and neoplasm.